Abstract | AIM: METHOD: Single-centre, retrospective cohort study of inborn preterm infants <32 weeks gestation (23-31(+6) ). RESULTS: Six hundred sixty-four preterm infants (<32 weeks) were born during the study period, of which 415 received surfactant ( poractant alfa: 214; beractant: 201). Infants in the poractant alfa group were 2.8 days younger than beractant (27.0 ± 2.3 vs. 27.4 ± 2.3 weeks; P = 0.03). All other baseline characters including Clinical Risk Index for Babies II scores were similar for both groups. No significant differences were found for the following outcomes: death or chronic lung disease (78/212 vs. 59/200; P = 0.28); death (24/214 vs. 15/201, P = 0.24); moderate to severe chronic lung disease (63/212 vs. 46/200; P = 0.45) and moderate to severe disability (20/163 vs. 19/151, P = 0.98) between poractant alfa and beractant, respectively. CONCLUSIONS:
|
Authors | Saritha Paul, Shripada Rao, Rolland Kohan, Judy McMichael, Noel French, Guicheng Zhang, Karen Simmer |
Journal | Journal of paediatrics and child health
(J Paediatr Child Health)
Vol. 49
Issue 10
Pg. 839-44
(Oct 2013)
ISSN: 1440-1754 [Electronic] Australia |
PMID | 23802801
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 The Authors. Journal of Paediatrics and Child Health © 2013 Paediatrics and Child Health Division (Royal Australasian College of Physicians). |
Chemical References |
- Biological Products
- Phospholipids
- Pulmonary Surfactants
- poractant alfa
- beractant
|
Topics |
- Biological Products
(therapeutic use)
- Humans
- Infant, Newborn
- Infant, Premature
- Phospholipids
(therapeutic use)
- Pulmonary Surfactants
(therapeutic use)
- Respiratory Distress Syndrome, Newborn
(drug therapy, mortality)
- Retrospective Studies
- Treatment Outcome
|